Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL.
Orlowski RZ, et al. Among authors: novick sc.
J Clin Oncol. 2002 Nov 15;20(22):4420-7. doi: 10.1200/JCO.2002.01.133.
J Clin Oncol. 2002.
PMID: 12431963
Clinical Trial.